Maintenance therapy after radiation for limited spread kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether giving a maintenance medication (pembrolizumab) after targeted radiation helps keep kidney cancer that has spread to a few spots (5 or fewer) from growing. You would receive radiation to each spot and then be randomly assigned to receive either the medication or a placebo (inactive substance) for up to about 2 years.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have kidney cancer that is the clear cell type.
- Your cancer has spread to 5 or fewer places in your body (like spots in your lungs, lymph nodes, or brain).
- You have not had immunotherapy (like pembrolizumab or nivolumab) in the last 6 months or other cancer medications in the last month.
- You are generally up and about (able to do daily activities with little help).
- Your blood counts, kidney, and liver function are within a safe range (checked by a blood test within 10 days).
- You are willing to have a biopsy (a small sample taken) of one of the spots that will be treated with radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether targeted external-beam radiation (SBRT) can control a small number of progressing kidney cancer spots while you continue immune checkpoint inhibitor immunotherapy. It may help shrink or stop those specific “oligoprogressive” lesions and prolong benefit from your current immunotherapy.
This trial tests whether targeted, high-precision radiation (stereotactic radiotherapy) can control a small number of growing kidney cancer metastases while you continue systemic treatment. It may help people who have “oligoprogressive” disease, where only 1–3 spots are getting worse.
This trial tests whether adding radiation to standard drug therapy helps control kidney cancer that has spread to a few spots (oligometastatic). It is for people with clear cell renal cell carcinoma who have up to 5 metastases.
This trial tests a combination of targeted radiation, an oral drug (axitinib), and an immunotherapy (toripalimab) for people with kidney cancer that has spread to a few spots. It aims to see if this combo helps control the cancer longer.
This trial tests whether adding a special type of radiation to your current immunotherapy can help shrink kidney cancer tumors that have stopped responding or are stable. The goal is to see if the radiation can boost the immune system's ability to fight cancer elsewhere in the body.
This trial tests whether combining focused radiation (SBRT) with anlotinib and bimepolizumab can shrink or slow kidney cancer that has spread and cannot be surgically removed. It's designed for people with a specific type of kidney cancer who are generally healthy enough to handle these treatments.
Hear when a new Oligometastatic Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.